



April 28, 2025

Company: Ono Pharmaceutical Co., Ltd.
 Representative: Toichi Takino
 Representative Director, President and COO
 (Securities Code: 4528 Prime market, TSE)
 Contact: Ryuta Imura
 Senior Director, Corporate Communications
 (Phone: +81-6-6263-5670)

Revisions of Consolidated Financial Forecasts

Osaka, Japan, April 28, 2025 - Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino) today announced that it has revised its consolidated financial forecasts for the full-year period ending March 2025 disclosed at the announcement of Q2 financial results ending March 2025, made on October 31, 2024, as follows:

<IFRS (Full) basis>

1. Revisions to the Full-Year Consolidated Financial Forecasts Ending March 2025 (April 1, 2024 – March 31, 2025)

(Millions of yen, except basic earnings per share)

	Revenue	Operating profit	Profit before tax	Profit for the year	Profit for the year attributable to owners of the Company	Basic earnings per share (yen)
Previous forecast (A)	485,000	82,000	81,500	58,100	58,000	123.49
Revised forecast (B)	487,000	60,000	60,000	51,000	50,000	106.46
Change (B-A)	2,000	(22,000)	(21,500)	(7,100)	(8,000)	-
Change (%)	0.4%	(26.8%)	(26.4%)	(12.2%)	(13.8%)	-
(Reference) Consolidated result of FY2023	502,672	159,935	163,734	128,040	127,977	266.61

2. Reasons for the differences

Revenue is forecasted to be ¥487.0 billion, an upward revision of ¥2.0 billion from the previously announced forecast. This increase is mainly due to royalty income from Bristol Myers Squibb for OPDIVO Intravenous Infusion is expected to exceed the previously announced forecast. Operating profit is forecasted to be ¥60.0 billion, a decrease of ¥22.0 billion from the previously announced forecast, mainly due to several factors: a sales milestone of ¥13.6 billion was recorded for FORXIGA Tablets, which were sold under a co-promotion agreement with AstraZeneca; amortization expenses were increased by approximately ¥7.0 billion compared to the previously announced forecast due to the revision of the amortization method for the increase in fair value of recognized inventory assets, related to the acquisition of Deciphera Pharmaceuticals, into the basis of actual inventory turnover; and the impairment loss of ¥2.5 billion on intangible assets was recorded for ONO-7018 (MALT1 inhibitor) due to the discontinuation of development.

Profit for the year attributable to owners of the Company is forecasted to be ¥50.0 billion, a decrease of ¥8.0 billion from the previously announced forecast due to the expected decrease of tax expense by ¥14.0 billion mainly related to the increase in tax credit for research and

development expenses, despite the expectation that the profit before tax is forecasted to be ¥60.0 billion, a decrease of ¥21.5 billion.

<Core basis>

1. Revisions to the Full-Year Consolidated Financial Forecasts Ending March 2025 (April 1, 2024 – March 31, 2025)

(Millions of yen, except basic earnings per share)

	Revenue	Core operating profit	Core profit for the year	Basic core earnings per share (yen)
Previous forecast (A)	485,000	110,000	81,000	172.46
Revised forecast (B)	487,000	113,000	90,000	191.63
Change (B-A)	2,000	3,000	9,000	-
Change (%)	0.4%	2.7%	11.1%	-
(Reference) Consolidated result of FY2023	502,672	180,925	142,545	296.96

2. Reasons for the differences

Revenue is the same as on a IFRS (full) basis. Core operating profit is forecasted to be ¥113.0 billion, an upward revision of ¥3.0 billion from the previously announced forecast mainly due to an increase in gross profit. The following factors mentioned in operating profit of IFRS (Full) basis are deducted: the sales milestone of ¥13.6 billion for FORXIGA Tablets, the financial effect due to the revision of the amortization method for the increase in fair value of recognized inventory assets related to the acquisition of Deciphera Pharmaceuticals, and the impairment loss of ¥2.5 billion on intangible assets for ONO-7018 (MALT1 inhibitor). Core profit for the year is forecasted to be ¥90.0 billion, an upward revision of ¥9.0 billion from the previously announced forecast due to an expected decrease of tax expense by ¥6.0 billion mainly related to the increase in tax credit for research and development expenses.

Note: The financial forecasts and statements contained in this announcement are prepared based on information that is available as of the date the announcement is made. Actual results may differ from those set forth in the announcements due to various uncertain factors.

*Definition of core basis

Core financial results are calculated by deducting items that are not inherently related to the Company's business performance or are one-time occurrences from the IFRS-based financial results. Adjustment items include amortization expenses arising from intangible assets acquired through acquisitions or in-licensing, impairment losses, compensation or settlement costs from litigation, and losses due to disasters.